End-of-day quote
Taipei Exchange
06:00:00 2024-07-10 pm EDT
|
5-day change
|
1st Jan Change
|
20.2
TWD
|
+0.50%
|
|
+5.76%
|
-2.88%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
714.4
|
743.9
|
1,117
|
1,126
|
1,257
|
1,507
|
Enterprise Value (EV)
1 |
424.9
|
375.6
|
660
|
1,105
|
1,169
|
1,537
|
P/E ratio
|
-11.8
x
|
8.83
x
|
1,932
x
|
60.8
x
|
17.3
x
|
-8.8
x
|
Yield
|
-
|
9.34%
|
-
|
-
|
0.5%
|
-
|
Capitalization / Revenue
|
1.63
x
|
1.74
x
|
2.52
x
|
2.89
x
|
3
x
|
3.8
x
|
EV / Revenue
|
0.97
x
|
0.88
x
|
1.49
x
|
2.83
x
|
2.79
x
|
3.88
x
|
EV / EBITDA
|
-16.9
x
|
8.88
x
|
17.5
x
|
1,358
x
|
-216
x
|
-31.4
x
|
EV / FCF
|
6.31
x
|
4.05
x
|
-11.4
x
|
-8.93
x
|
-11.2
x
|
-7
x
|
FCF Yield
|
15.9%
|
24.7%
|
-8.76%
|
-11.2%
|
-8.97%
|
-14.3%
|
Price to Book
|
1.18
x
|
1.08
x
|
1.66
x
|
1.66
x
|
1.59
x
|
1.97
x
|
Nbr of stocks (in thousands)
|
60,230
|
60,230
|
60,230
|
60,230
|
64,288
|
72,448
|
Reference price
2 |
11.86
|
12.35
|
18.55
|
18.69
|
19.56
|
20.80
|
Announcement Date
|
4/30/19
|
4/30/20
|
4/27/21
|
4/26/22
|
4/25/23
|
4/15/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
438.7
|
427.7
|
443.2
|
390
|
419
|
396.1
|
EBITDA
1 |
-25.17
|
42.31
|
37.72
|
0.814
|
-5.413
|
-49.01
|
EBIT
1 |
-64.68
|
8.491
|
6.596
|
-28.66
|
-33.52
|
-81.9
|
Operating Margin
|
-14.74%
|
1.99%
|
1.49%
|
-7.35%
|
-8%
|
-20.67%
|
Earnings before Tax (EBT)
1 |
-67.37
|
12.89
|
-3.103
|
12.09
|
72.26
|
-167.9
|
Net income
1 |
-60.55
|
84.94
|
0.619
|
18.74
|
71.6
|
-168.1
|
Net margin
|
-13.8%
|
19.86%
|
0.14%
|
4.81%
|
17.09%
|
-42.43%
|
EPS
2 |
-1.009
|
1.399
|
0.009600
|
0.3076
|
1.127
|
-2.364
|
Free Cash Flow
1 |
67.38
|
92.72
|
-57.84
|
-123.7
|
-104.8
|
-219.7
|
FCF margin
|
15.36%
|
21.68%
|
-13.05%
|
-31.73%
|
-25.02%
|
-55.45%
|
FCF Conversion (EBITDA)
|
-
|
219.17%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
109.17%
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
1.153
|
-
|
-
|
0.0980
|
-
|
Announcement Date
|
4/30/19
|
4/30/20
|
4/27/21
|
4/26/22
|
4/25/23
|
4/15/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
30.6
|
Net Cash position
1 |
289
|
368
|
457
|
21
|
88.2
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-0.6239
x
|
Free Cash Flow
1 |
67.4
|
92.7
|
-57.8
|
-124
|
-105
|
-220
|
ROE (net income / shareholders' equity)
|
-9.61%
|
1.24%
|
-0.18%
|
1.52%
|
9.75%
|
-21.6%
|
ROA (Net income/ Total Assets)
|
-4.52%
|
0.6%
|
0.4%
|
-1.78%
|
-2.12%
|
-4.54%
|
Assets
1 |
1,339
|
14,220
|
155.4
|
-1,051
|
-3,372
|
3,700
|
Book Value Per Share
2 |
10.10
|
11.50
|
11.20
|
11.30
|
12.30
|
10.60
|
Cash Flow per Share
2 |
4.000
|
6.660
|
7.920
|
1.780
|
4.930
|
3.490
|
Capex
1 |
18.3
|
21
|
42.7
|
93.6
|
94.1
|
150
|
Capex / Sales
|
4.16%
|
4.91%
|
9.63%
|
24%
|
22.45%
|
37.93%
|
Announcement Date
|
4/30/19
|
4/30/20
|
4/27/21
|
4/26/22
|
4/25/23
|
4/15/24
|
|
1st Jan change
|
Capi.
|
---|
| -2.88% | 45.09M | | +23.50% | 47.07B | | +47.02% | 42.06B | | -5.16% | 39.98B | | +36.37% | 33.02B | | -7.79% | 27.9B | | +18.06% | 27.63B | | +47.29% | 14.37B | | +41.91% | 13.45B | | -1.02% | 12.03B |
Other Biotechnology & Medical Research
|